ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Thermo Fisher to invest $475 million in biopharmaceutical services

by Rick Mullin
March 27, 2020 | APPEARED IN VOLUME 98, ISSUE 12

 

Thermo Fisher Scientific says it will spend more than $475 million on biopharmaceutical capabilities and capacity this year. Investments will target biologics, cell and gene therapy, drug product development, and commercialization support, including spray drying. The company plans to open a Bioprocessing Collaboration Center in July at its Saint Louis facility, where it recently completed a $50 million expansion. It also plans to open a cell therapy development and production center in Princeton, New Jersey, this year. Thermo Fisher became a powerhouse in drug services in 2017, when it bought Patheon for $7.2 billion. It expanded into cell and gene therapies last year by acquiring Brammer Bio for $1.7 billion.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment